Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Equity (2016 - 2025)

Celldex Therapeutics (CLDX) has 15 years of Return on Equity data on record, last reported at 0.46% in Q4 2025.

  • For Q4 2025, Return on Equity fell 25.0% year-over-year to 0.46%; the TTM value through Dec 2025 reached 0.46%, down 25.0%, while the annual FY2025 figure was 0.41%, 14.0% down from the prior year.
  • Return on Equity reached 0.46% in Q4 2025 per CLDX's latest filing, down from 0.36% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.17% in Q4 2021 and bottomed at 0.48% in Q3 2023.
  • Average Return on Equity over 5 years is 0.3%, with a median of 0.3% recorded in 2025.
  • Peak YoY movement for Return on Equity: grew 28bps in 2024, then dropped -25bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.17% in 2021, then crashed by -102bps to 0.33% in 2022, then decreased by -25bps to 0.42% in 2023, then surged by 51bps to 0.21% in 2024, then tumbled by -123bps to 0.46% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.46% in Q4 2025, 0.36% in Q3 2025, and 0.29% in Q2 2025.